SCPS (Scopus BioPharma) Institutional Ownership: 0.00% (As of Jul. 02, 2026)


What is Scopus BioPharma Institutional Ownership?

Scopus BioPharma SCPS Institutional Ownership is 0.00% as of Jul. 02, 2026.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Scopus BioPharma's institutional ownership is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Scopus BioPharma's Insider Ownership is 1.21%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Scopus BioPharma's Float Percentage Of Total Shares Outstanding is 81.32%.

Scopus BioPharma Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Scopus BioPharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scopus BioPharma Institutional Ownership Chart

Scopus BioPharma Historical Data

The historical data trend for Scopus BioPharma can be seen below:

2022-03-31 2022-04-30 2022-05-31 2022-06-30 2022-07-31 2022-08-31 2022-09-30 2022-10-31 2022-11-30 2022-12-31
Institutional Ownership 5.58 5.57 5.57 2.54 2.12 2.10 1.70 1.70 1.70 0.34

Scopus BioPharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.00% mean?
Scopus BioPharma (SCPS) has a Institutional Ownership of 0.00% as of Jul. 02, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Scopus BioPharma and its competitors.
Is Scopus BioPharma's Institutional Ownership too high?
Scopus BioPharma's current Institutional Ownership is 0.00%.
How does Scopus BioPharma's Institutional Ownership compare to AMPE and DRMA?
Scopus BioPharma's Institutional Ownership of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Scopus BioPharma and its competitors. Scopus BioPharma's current Institutional Ownership is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scopus BioPharma stock overvalued right now?
Scopus BioPharma (SCPS) has a current Institutional Ownership of 0.00%. The current Institutional Ownership is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Scopus BioPharma (SCPS), the current Institutional Ownership is 0.00% as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scopus BioPharma Business Description

Address 420 Lexington Avenue, Suite 300, New York, NY, USA, 10170
Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.